Zhang Jia-Jia, Liu Wei, Xing Guo-Zhen, Xiang Li, Zheng Wen-Ming, Ma Zhen-Ling
College of Life Sciences, Henan Agricultural University, Zhengzhou, 450002, China.
Henan Provincial People's Hospital/People's Hospital of Zhengzhou University, 7 Weiwu Road, Jinshui District, Zhengzhou, 450000, China.
Cancer Cell Int. 2022 Nov 19;22(1):361. doi: 10.1186/s12935-022-02763-z.
Gynecological cancer is one of the most severe diseases that threaten the lives and health of women worldwide. Its incidence rate increases with each passing year and becomes more prevalent among young people. The prognosis of gynecological cancer remains poor despite significant advances in surgical removal and systemic chemotherapy. Several chemokines play a role in the progression of gynecologic cancers. CCL2 (CC-chemokine ligand 2), also termed MCP-1 (monocyte chemotactic protein 1), plays a significant physiological role in monocyte cell migration and the inflammatory response. Recent studies have demonstrated that CCL2 plays a pro-tumorigenic function in the tumor microenvironment. According to previous studies, CCL2 plays a significant role in the occurrence and development of gynecological cancers. Furthermore, recent studies noted that CCL2 could be a potential diagnostic biomarker and prognostic predictor. The purpose of this paper is to review the role of CCL2 in the occurrence and development of gynecological cancers and to discuss the potential therapeutic strategy of CCL2 for gynecological cancers, with a primary focus on breast cancer, ovarian cancer, cervical cancer, and endometrial cancer.
妇科癌症是威胁全球女性生命健康的最严重疾病之一。其发病率逐年上升，且在年轻人中更为普遍。尽管手术切除和全身化疗取得了显著进展，但妇科癌症的预后仍然很差。几种趋化因子在妇科癌症的进展中发挥作用。CCL2（CC趋化因子配体2），也称为MCP-1（单核细胞趋化蛋白1），在单核细胞迁移和炎症反应中发挥重要的生理作用。最近的研究表明，CCL2在肿瘤微环境中发挥促肿瘤发生功能。根据以往的研究，CCL2在妇科癌症的发生和发展中起重要作用。此外，最近的研究指出，CCL2可能是一种潜在的诊断生物标志物和预后预测指标。本文旨在综述CCL2在妇科癌症发生和发展中的作用，并探讨CCL2对妇科癌症的潜在治疗策略，主要关注乳腺癌、卵巢癌、宫颈癌和子宫内膜癌。
